Igg4-related Disease
📧 Sign up to get email alerts when something new happens for Igg4-related Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Ambispective Validation of the Odesa Criteria 2026 (OC26): A Flexible Point-Based System for Diagnosis of Autoimmune Pancreatitis.
The document describes a planned ambispective validation study of the Odesa Criteria 2026 for diagnosing autoimmune pancreatitis and related…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA. [Phase 2, Phase 3]
The trial evaluates the diagnostic performance of the radiotracer [18F]-AlF-FAPI-74 PET/CT for inflammatory disorders and compares it with F…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease [Phase 3]
Sanofi's Phase 3 trial is evaluating rilzabrutinib versus placebo for immunoglobulin G4-related disease, with recruitment ongoing.
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement [NA]
This document reports a recruiting clinical trial investigating treatment strategies for patients with IgG4-related disease involving superf…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease [Phase 1, Phase 2]
Acepodia Biotech is conducting a Phase 1/2 clinical trial to assess safety, efficacy, and persistence of ACE1831 in IgG4-related disease, wi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Study of Efgartigimod in Patients With IgG4-Related Disease [Phase 2]
This is a Phase 2 study of efgartigimod in patients with IgG4-related disease, currently recruiting. The trial is sponsored by Stanford Univ…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease [Phase 3]
A Phase 3 study evaluating Obexelimab for IgG4-related disease is active but not recruiting. The sponsor is Zenas BioPharma (USA), LLC.
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease [Phase 2, Phase 3]
A randomized study to assess lenalidomide for active IgG4-related disease is in Phase 2 and Phase 3, and recruitment is ongoing.
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease [EARLY_Phase 1]
An early-phase exploratory study to assess the safety and efficacy of a CD19/BCMA CAR-NK cell therapy for relapsed and refractory IgG4-relat…
-
CLINICAL_TRIALS research · 2025-09-03Clinical Trial Update: Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease [Phase 2]
A Phase 2 exploratory study is evaluating an anti-BCMA-CD19 CAR-T cell therapy for relapsed or refractory IgG4-related disease; the trial is…
-
CLINICAL_TRIALS research · 2025-08-05Clinical Trial Update: A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD [NA]
This clinical trial update describes a study evaluating whether measurable residual disease detected by FAPI PET/CT can predict recurrence i…
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases [Phase 1]
A Phase 1 clinical trial evaluating YTS109 cell therapy for relapsed/refractory autoimmune diseases is currently recruiting. The study cover…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases [Phase 1]
Phase 1 clinical trial evaluating a BCMA/CD19 dual-targeted CAR-T cell therapy for autoimmune kidney diseases, currently recruiting.
-
CLINICAL_TRIALS research · 2025-05-18Clinical Trial Update: UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases [Phase 1]
Phase 1 clinical trial update for UCAR T-cell therapy targeting CD19/BCMA in relapse/refractory autoimmune diseases. The study includes seve…
-
CLINICAL_TRIALS research · 2025-04-30Clinical Trial Update: Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
This entry notes an active-not-recruiting clinical trial at IRCCS San Raffaele investigating adaptive and trained immunity in the pathogenes…
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: AYLo - AutoimmunitY and Loss of y
Clinical trial AYLo from the University of Bonn investigates autoimmunity across multiple diseases and is currently recruiting.
-
CLINICAL_TRIALS research · 2024-10-29Clinical Trial Update: Short-term Glucocorticoid Combined with MMF for IgG4-RD [NA]
A clinical trial update indicates recruitment is ongoing for a study evaluating short-term glucocorticoid therapy combined with mycophenolat…
-
CLINICAL_TRIALS research · 2024-10-23Clinical Trial Update: Key Mechanisms of Abnormal T Cell Activation and Differentiation in IgG4-Related Ophthalmic Disease
This clinical-trial update explores the key mechanisms of abnormal T cell activation and differentiation in IgG4-related ophthalmic disease.
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: AMG 335 Expanded Access Program for IgG4-Related Disease
Amgen's update notes that AMG 335 (talquetamab) Expanded Access is available for patients with IgG4-related disease, under the Amgen program…
-
CLINICAL_TRIALS research · 2024-07-11Clinical Trial Update: Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease [EARLY_Phase 1]
An early-phase clinical trial (Phase 1) is evaluating the safety and potential efficacy of PRG-2311 for refractory lupus nephritis and IgG4-…
-
CLINICAL_TRIALS research · 2024-07-11Clinical Trial Update: Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease [EARLY_Phase 1]
Early-phase clinical trial evaluating safety and efficacy of PRG-1801 for lupus nephritis and IgG4-related disease is currently recruiting.
-
CLINICAL_TRIALS research · 2024-06-26Clinical Trial Update: Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases [Phase 2]
A Phase 2 clinical trial update for rediscovering a drug for rare immune-mediated inflammatory diseases, with recruitment ongoing for Behçet…
-
CLINICAL_TRIALS research · 2024-05-28Clinical Trial Update: Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement [NA]
Clinical trial update on treatment strategies for IgG4-related disease with internal organ involvement; currently recruiting.
-
CLINICAL_TRIALS research · 2018-04-11Clinical Trial Update: To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom [Phase 4]
A Phase 4 clinical trial update evaluating the efficacy of Iguratimod in mild IgG4-related disease.
-
CLINICAL_TRIALS research · 2018-03-16Clinical Trial Update: Plasmablast Detection From IgG4-Related Disease Patients
This clinical trial update reports on detecting plasmablasts in patients with IgG4-related disease, with the study status listed as unknown.